351 Shares in McKesson Co. (NYSE:MCK) Bought by Talbot Financial LLC

Talbot Financial LLC bought a new stake in shares of McKesson Co. (NYSE:MCK) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 351 shares of the company’s stock, valued at approximately $200,000.

Several other institutional investors also recently bought and sold shares of MCK. Wolff Wiese Magana LLC raised its holdings in McKesson by 742.9% during the third quarter. Wolff Wiese Magana LLC now owns 59 shares of the company’s stock valued at $29,000 after buying an additional 52 shares in the last quarter. MidAtlantic Capital Management Inc. bought a new position in McKesson during the third quarter valued at about $29,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of McKesson in the third quarter valued at about $31,000. ORG Wealth Partners LLC acquired a new stake in shares of McKesson in the third quarter valued at about $40,000. Finally, Bruce G. Allen Investments LLC grew its position in shares of McKesson by 51.9% in the fourth quarter. Bruce G. Allen Investments LLC now owns 82 shares of the company’s stock valued at $47,000 after purchasing an additional 28 shares during the last quarter. 85.07% of the stock is currently owned by institutional investors.

McKesson Stock Performance

NYSE MCK traded up $7.17 during trading hours on Monday, hitting $588.91. 232,125 shares of the company traded hands, compared to its average volume of 558,860. The business’s 50-day moving average is $592.54 and its 200-day moving average is $560.89. McKesson Co. has a twelve month low of $464.42 and a twelve month high of $637.51. The stock has a market capitalization of $74.76 billion, a price-to-earnings ratio of 30.50, a P/E/G ratio of 1.25 and a beta of 0.52.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $7.07 EPS for the quarter, beating the consensus estimate of $6.88 by $0.19. The firm had revenue of $93.65 billion during the quarter, compared to analysts’ expectations of $89.33 billion. McKesson had a negative return on equity of 207.50% and a net margin of 0.77%. The business’s quarterly revenue was up 21.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.23 earnings per share. Analysts predict that McKesson Co. will post 32.73 EPS for the current year.

McKesson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, January 2nd. Stockholders of record on Monday, December 2nd were paid a dividend of $0.71 per share. The ex-dividend date was Monday, December 2nd. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.48%. McKesson’s dividend payout ratio (DPR) is currently 14.71%.

Insider Transactions at McKesson

In other McKesson news, EVP Leann B. Smith sold 579 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $572.79, for a total value of $331,645.41. Following the sale, the executive vice president now owns 864 shares of the company’s stock, valued at approximately $494,890.56. This trade represents a 40.12 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.11% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Baird R W raised McKesson from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft cut their price objective on McKesson from $623.00 to $579.00 and set a “buy” rating for the company in a research report on Wednesday, September 25th. Morgan Stanley lifted their price objective on McKesson from $612.00 to $642.00 and gave the company an “overweight” rating in a research report on Tuesday, December 17th. Robert W. Baird upgraded McKesson from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $531.00 to $688.00 in a research report on Thursday, November 7th. Finally, Bank of America dropped their target price on McKesson from $680.00 to $650.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Two research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $646.14.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.